Bryan C. Markinson, DPM, joins iRemedy Medical Advisory Board
STUART, FL – April, 2017 – The iRemedy Healthcare Companies, Inc. today announced the addition of Bryan C. Markinson, DPM, to iRemedy’s Medical Advisory Board.
“Bryan is a highly respected and influential leader nationally in the practice of podiatric medicine. It is an honor having him join our Advisory Board and his contributions will be key as we plan the further development of our podiatric community”, stated Tony Paquin, CEO of iRemedy Healthcare.
Bryan C. Markinson, DPM is currently the Chief of Podiatric Medicine and Surgery and Associate Professor in the Leni and Peter W. May Department of Orthopedic Surgery of the Icahn School of Medicine at Mount Sinai in New York City. He is a 1981 graduate of the New York College of Podiatric Medicine and is certified by The American Board of Podiatric Medicine. Always interested in podiatric dermatology, he served as a Fellow from September 1993 to June 1995 in the department of Dermatopathology at the University of Medicine and Dentistry in New Jersey, under the direction of W. Clark Lambert, MD, PhD. Shortly thereafter, Dr. Markinson founded the Podiatric Pathology service at the Mount Sinai School of Medicine. He is also an instructor in the Department of Dermatologic Surgery and Team Member of the Skin Cancer and Melanoma Unit of the Tisch Cancer Center.
“The success of practices today, large or small, is increasingly dependent on preservation of the bottom line through adoption of efficiencies. The iRemedy platform seamlessly integrates into your existing work flow so that you can concentrate on patient care while enhancing your bottom line,” said Dr. Markinson.
Dr. Markinson is a frequent lecturer nationally on various aspects of podiatric dermatology and nail pathology. In 2004, he was elected to the Board of Trustees of the Council of Nail Disorders, a position he still holds. His areas of special interests are skin and nail fungal infections, pedal melanoma, soft tissue masses, pedal dermatitis, longitudinal melanonychia, and podiatric dermatological risk management. Dr. Markinson has been a consultant to Bako Podiatric Pathology Laboratories since its inception, and several pharmaceutical companies in the dermatology space.
About The iRemedy Healthcare Companies, Inc.
Headquartered in Stuart, Florida, The iRemedy Healthcare Companies, Inc. is nationally recognized as the incumbent leader in the delivery of “Retail Healthcare” products, end-to-end distribution and fulfillment services and innovative Digital Health solutions to U.S. healthcare providers and their consumers. iRemedy offers healthcare providers the ability to save costs on medical supplies and generate new and meaningful retail revenue streams through leading edge patient engagement tools and services offered on its proprietary platform. For more information, please visit www.iRemedySupply.com. andwww.iRemedy.com.